AMR Benchmark homepage

News - 18 Nov 2021

Now online: 2021 AMR Benchmark

Pharma companies press on in fight against superbugs despite COVID-19 pandemic. But action to improve global access to antibiotics still lags. The AMR Benchmark tracks 17 of the world’s largest pharma companies on their efforts against drug resistance.

The AMR Benchmark: tracking pharma’s response to drug resistance

The 2021 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are tackling this crisis. This independent report covers R&D, responsible manufacturing, access and stewardship.

"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”

Dame Sally Davies

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge

View our media coverage

Back to top |